8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 26, 2011

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	1-14041	04-2882273
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

400 Wood Road	02184
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
	Item 7.01 Regulation FD Disclosure.
	Item 9.01 Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
Ex-99.1

Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 26, 2011, Haemonetics Corporation announced that the Board of Directors elected Paul M. Black to join its Board effective immediately. Mr. Black will serve on the Board’s Audit and Compensation Committees, also effective immediately.

Mr. Black will receive the standard retainers and meeting fees payable to non-employee directors of the company, as described in the company’s Proxy Statement dated June 17, 2010. Also pursuant to these arrangements, Mr. Black will receive equity compensation valued at $200,000, half of which is granted as 6,002 shares in non-qualified stock options and half as 1,691 shares of restricted stock units. These shares will vest on the one year anniversary of the grant date.

Item 7.01 Regulation FD Disclosure.

The company’s press release announcing the election of Mr. Black is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated January 26, 2011 announcing the election of Paul M. Black to join Haemonetics Board of Directors.

2

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION (Registrant)
Date: January 26, 2011	/s/ Susan Hanlon
	Susan Hanlon, VP Finance

EXHIBIT INDEX

99.1 Press Release issued by Haemonetics Corporation on January 26, 2011 announcing the election of Paul M. Black to join Haemonetics Board of Directors.

EX-99.1

Exhibit 99.1

FOR RELEASE:		CONTACT:
Date	January 26, 2011	Bryanne Salmon
Time	4:00 pm Eastern	Tel. (781) 356-9613
		bsalmon@haemonetics.com

Paul M. Black Joins Haemonetics Board of Directors

Braintree, MA, January 26, 2011 — Haemonetics Corporation (NYSE:HAE) announced today that the Board of Directors elected Black to join its Board effective immediately.

Mr. Black, age 52, spent 13 years with Cerner Corporation, a publically traded global provider of healthcare information technology solutions. He retired as Cerner’s Chief Operating Officer in 2007. Prior to Cerner, Black was with IBM from 1982 to 1994, in a number of senior sales and professional services leadership positions.

Mr. Black currently serves on the Boards at Connextions, Inc., and Saepio Technologies, Inc., private companies with enterprise wide, integrated software and services information technology offerings, as well as the Board Chairman of Truman Medical Centers, a two hospital not-for-profit acute-care health system located in Kansas City.

Black is an Operating Executive for Genstar Capital, LLC, a San Francisco-based private equity firm that invests in leading middle-market companies as well as an Advisor to New Mountain’s debt effort, Guardian, which was established in 2008 to purchase debt securities.

Mr. Black has a BS degree from Iowa State University and an MBA from the University of Iowa.

Ron Gelbman, Lead Director of Haemonetics’ Board said, “Paul’s deep knowledge and experience scaling clinical information management systems to deliver clinical benefits and cost savings make him uniquely qualified to help guide the Company as we pursue blood management solutions that are leveraged through clinical information management systems.”

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

Haemonetics Corporation • 400 Wood Road • Braintree, MA 02184 USA